Financial Performance - The company's operating revenue for the reporting period was ¥1,185,567,446.50, a decrease of 7.49% compared to the same period last year[12]. - Net profit attributable to shareholders was ¥69,331,995.88, representing an increase of 111.64% year-on-year[12]. - The net profit after deducting non-recurring gains and losses was ¥64,735,333.60, up 254.96% from the previous year[12]. - The net cash flow from operating activities was ¥7,412,539.62, down 85.29% compared to the same period last year[12]. - Basic and diluted earnings per share were both ¥0.19, reflecting an increase of 111.11% year-on-year[12]. - Total assets at the end of the reporting period were ¥2,707,964,380.40, an increase of 1.85% from the end of the previous year[12]. - Net assets attributable to shareholders were ¥1,998,518,384.13, up 0.76% compared to the end of the previous year[12]. - The company achieved a net profit of 69.33 million yuan in the first half of 2024, representing a year-on-year increase of 111.64%[131]. - Total operating revenue for the reporting period was 1,185,567,446.50 yuan, a decrease of 7.49% compared to 1,281,583,508.22 yuan in the same period last year[136]. - The gross profit margin improved to 11.82% in the food manufacturing sector, up by 2.70% year-on-year[138]. - The functional sugar segment generated revenue of 427,633,758.83 yuan, with a gross profit margin of 15.00%, reflecting an increase of 11.95% in revenue year-on-year[138]. Market Position and Strategy - The company is a leading player in the functional sugar industry, focusing on enzyme engineering and fermentation technology for over 20 years[17]. - The company has established itself as a leader in the industrial production of functional sugars, including isomaltodextrin, fructooligosaccharides, and erythritol, with significant production capacity in China[68]. - The company has developed a complete industrial chain for erythritol production, which has gained wide market recognition and is expected to enhance revenue capabilities from new projects[180]. - The company is facing increased competition in the erythritol market, leading to price reductions, although prices have started to rise again from the bottom[180]. - The company has a strong market presence as one of the earliest enterprises to industrialize functional sugars in China, leading the industry with significant advantages[111]. - The company aims to expand its market presence through innovative product lines and strategic partnerships[9]. - The company is positioned to leverage its production and application technology advantages to expand the use of erythritol as a preferred sugar substitute[80]. - The company plans to enhance market development for new products and improve the profitability of new projects[181]. Product Development and Innovation - The semi-annual report outlines the company's commitment to research and development of new products and technologies[9]. - The company has successfully developed and industrialized new products such as allulose, GOS/FOS, and 2'-FL, enhancing its functional sugar product system[93]. - The company has developed over 90 types of functional sugar products, including low oligosaccharides and erythritol, establishing a comprehensive innovation system that links basic research, engineering technology, and application solutions[105]. - The company is investing in research and development to optimize processes for prebiotics, dietary fibers, and sugar substitutes, maintaining a technological edge[131]. - The company plans to launch new high-end products such as sugar-free low-water activity oligosaccharides and dietary fibers, with future products including HMO (human milk oligosaccharides), DHA, and lactulose[119]. Health and Nutrition Focus - The company focuses on functional foods that regulate physiological activities without treating diseases[8]. - The report includes various definitions related to low-sugar and functional sugars, indicating a focus on health-oriented products[8]. - The company emphasizes the importance of dietary fibers and prebiotics in its product offerings, which are beneficial for gut health[8]. - The company is committed to advancing the health food industry by developing functional proteins, dietary fibers, and probiotics[91]. - The health food industry in China has rapidly developed due to increased awareness of health issues related to imbalanced diets, leading to a growing demand for preventive and therapeutic functional foods[49]. Supply Chain and Cost Management - The company has established a stable and efficient supply chain system to maximize collaborative value and transform the supply chain into a value chain[119]. - The company has seen a decrease in raw material and energy costs compared to the same period in 2023, contributing to improved cost management[119]. - The company is actively improving production processes to reduce raw material consumption and phase out low-margin production lines, aiming for a transition to high-margin products[157]. - The company has implemented a "small, fine, and flexible" business model, focusing on high-value-added and flexible businesses to better meet customer needs and target high-profit, differentiated markets[119]. Research and Development Collaborations - The company has established partnerships with leading research institutions to enhance its R&D capabilities in enzyme and fermentation technologies[92]. - The company has participated in formulating over 40 international, national, and industry standards, showcasing its influence in the sector[92]. - The company is aligned with national health initiatives, focusing on reducing sugar intake and promoting healthy dietary habits[91]. Risks and Challenges - The company faces risks related to raw material price fluctuations, downstream customer demand volatility, and intensified industry competition[195]. - The domestic and international fructose syrup markets are relatively saturated, and profitability is limited due to fluctuations in raw material prices[87]. - The company engaged in hedging activities to mitigate market risks, with a total fair value change loss of 404.34 thousand yuan during the reporting period[168].

证券代码：002286 证券简称：保龄宝 公告编号：2024-051 保龄宝生物股份有限公司 根据《公司法》、《证券法》、《公司章程》及其他有关规定，经董事会认真审 核，认为《公司 2024 年半年度报告》及其摘要的编制和审核程序符合法律法规 及相关监管规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在 任何虚假记载、误导性陈述或者重大遗漏。 详情见与本决议公告同日发布在指定信息披露媒体上的《保龄宝生物股份有 限公司 2024 年半年度报告摘要》、《保龄宝生物股份有限公司 2024 年半年度报 告》。 第六届董事会第二次会议决议公告 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、会议召开情况 保龄宝生物股份有限公司（以下简称"保龄宝"或"公司"）关于召开第六 届董事会第二次会议的通知于 2024 年 7 月 19 日以电子邮件的方式发出，会议于 2024 年 7 月 30 日以通讯表决的方式召开。会议应参加表决的董事 8 人，实际表 决的董事 8 人。会议的召开符合《公司法》和《公司章程》等法规的规定。 二、会议审议情况 会议以 8 票同意、0 ...

关于欧盟对中国赤藓糖醇反倾销调查初裁结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002286 证券简称：保龄宝 公告编号：2024-050 保龄宝生物股份有限公司 的关税，对保龄宝在欧盟的赤藓糖醇业务的影响是相对正面和积极的。 根据欧盟反倾销调查程序，本次欧盟委员会的反倾销税率为初裁结果，最终 反倾销税率尚需等待最终裁定结果，存在反倾销税率变动的风险。公司将继续关 注欧盟反倾销终裁结果的进展情况，并及时履行信息披露义务，敬请广大投资者 注意投资风险。 四、备查文件 保龄宝生物股份有限公司（以下简称"公司""保龄宝"）于近日收到代理 律师通知，欧盟 2024 年 7 月 19 日公布了对原产于中国的赤藓糖醇产品启动反倾 销调查的初步裁定结果。现将具体情况公告如下： 一、情况介绍 2023 年 11 月 21 日，欧盟委员会发布公告，决定对原产于中国的赤藓糖醇 产品（Erythritol）发起反倾销调查。涉案产品海关税则号编码为 2905 49 00 15, 2106 90 92 65 和 2106 90 98 15。案件调查期为 202 ...

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 58 million and 75 million CNY, representing a year-on-year increase of 77.05% to 128.94% compared to 32.76 million CNY in the same period last year [2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 57 million and 70 million CNY, reflecting a year-on-year growth of 212.55% to 283.83% from 18.24 million CNY in the previous year [2]. - The basic earnings per share is projected to be between 0.1595 CNY and 0.2038 CNY, compared to 0.09 CNY in the same period last year [2]. - The performance forecast is based on preliminary estimates and has not been audited by an accounting firm; final financial data will be disclosed in the 2024 semi-annual report [5]. Cost Management - The company has optimized production processes for prebiotics, dietary fibers, and sugar substitute products, leading to a decrease in production costs compared to the same period last year [4]. - The prices of key raw materials such as corn and corn starch, as well as energy procurement costs, have decreased compared to the same period in 2023 [4]. Marketing Strategy - The company has adjusted its marketing strategy to enhance incentives for differentiated and high-margin products, resulting in an improved product structure and gross margin [4].

保龄宝生物股份有限公司 关于控股股东收到山东证监局警示函的公告 股票简称：保龄宝 股票代码：002286 公告编号：2024-048 如果对本监督管理措施不服，可以在收到本决定书之日起60日内向中国证券 监督管理委员会提出行政复议申请；也可以在收到本决定书之日起6个月内向有 管辖权的人民法院提起诉讼。复议与诉讼期间，上述监督管理措施不停止执行。" 二、相关说明 公司控股股东永裕投资收到行政监管措施决定书后，高度重视该决定书中指 出的问题，责任方将引以为戒、吸取教训，加强对相关法律法规的学习，进一步 强化合规和自律意识，积极配合上市公司做好信息披露工作。上述的监督管理措 施仅针对相关股东方执行，不涉及上市公司及公司的其他股东，亦不会影响上市 公司的正常生产经营。后续，上市公司将继续督促相关股东方等信息披露义务方 进一步加强法律、法规和规范性文件的学习，切实履行信息披露义务。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2024年6月21日，公司控股股东北京永裕投资管理有限公司(以下简称"永裕 投资")收到中国证券监督管理委员会山东监管局(以下简称 ...

Financial Performance - The company achieved operating revenue of CNY 551.22 million in Q1 2024, a decrease of 9.68% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 23.17 million, representing a year-on-year increase of 35.89%, exceeding the company's budget target[4]. - The net profit after deducting non-recurring gains and losses was CNY 20.32 million, up 59.01% year-on-year[8]. - Basic and diluted earnings per share increased by 20.00% to CNY 0.06 per share[8]. - Net profit for Q1 2024 increased to CNY 23,168,151.36, representing a growth of 36.1% compared to CNY 17,049,704.23 in Q1 2023[22]. - The net profit attributable to the parent company for Q1 2024 was ¥23,168,151.36, compared to ¥17,049,704.23 in Q1 2023, representing a year-over-year increase of approximately 36.9%[23]. - The total comprehensive income for Q1 2024 was ¥1,716,671.41, a significant decrease from ¥32,620,754.38 in Q1 2023[23]. Cash Flow - The company reported a significant decline in net cash flow from operating activities, amounting to CNY -14.44 million, a decrease of 1,385.25% compared to the previous year[8]. - Cash flow from operating activities showed a significant decline of 1385.25%, resulting in a net outflow of ¥14,443,157.72 due to increased raw material purchases[12]. - Cash inflows from operating activities totaled ¥607,571,686.93 in Q1 2024, down from ¥669,049,904.66 in Q1 2023, reflecting a decrease of approximately 9.2%[25]. - Cash outflows from operating activities were ¥622,014,844.65 in Q1 2024, compared to ¥667,926,138.90 in Q1 2023, showing a reduction of about 6.9%[25]. - The net cash flow from investing activities was -¥2,729,565.38 in Q1 2024, an improvement from -¥34,284,882.76 in Q1 2023[26]. - The net cash flow from financing activities for Q1 2024 was ¥10,815,989.77, compared to -¥19,788,346.69 in Q1 2023, indicating a positive shift in financing cash flow[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.65 billion, a slight decrease of 0.20% from the end of the previous year[8]. - The company’s total assets were CNY 2,653,608,973.27, slightly down from CNY 2,658,892,343.60 in Q1 2023[19]. - Total liabilities amounted to CNY 697,847,427.22, up 3.0% from CNY 675,406,526.56 year-over-year[19]. - Current assets totaled CNY 850,715,672.95, an increase of 8.3% from CNY 785,867,159.38 in the previous year[18]. - Accounts receivable rose to CNY 248,503,016.55, up 8.5% from CNY 229,110,279.30 year-over-year[18]. - Inventory increased to CNY 334,273,988.27, reflecting a growth of 20.0% compared to CNY 278,582,358.53 in Q1 2023[18]. Operational Focus and Strategy - The company is focusing on high-margin, differentiated markets and has seen an increase in sales volume and revenue in its core business despite a decline in feed business revenue[4]. - The company is actively expanding into new markets and applications, such as HMO and high-end modified starch, to gain a competitive edge[5]. - The company plans to continue its business transformation in Q2, focusing on high-profit businesses and improving operational efficiency[6]. - The company aims to achieve rapid growth through both organic growth and strategic acquisitions[7]. Expenses - The company reported a decrease in management expenses to CNY 16,276,681.21, down 43.1% from CNY 28,737,542.72 in Q1 2023[22]. - Research and development expenses were CNY 1,476,414.79, a decrease of 17.6% compared to CNY 1,791,989.02 in the same quarter last year[22]. - Financial expenses decreased by 86.8% to ¥935,926.19 due to significant exchange rate fluctuations in the previous year[12]. Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 36,559[14]. - The largest shareholder, Beijing Yongyu Investment Management Co., Ltd., holds 12.65% of shares, totaling 46,888,790 shares[14].

证券简称：保龄宝 证券代码：002286 公告编号：2024-037 保龄宝生物股份有限公司 关于 2021 年股票期权与限制性股票激励计划 部分限制性股票回购注销完成的公告 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 重要内容提示： ●本次回购注销事项涉及130名激励对象，回购注销的限制性股票数量合计 100.3200万股 ，占 回购注 销前 公司总 股本 的0.27% ， 回购 金额为 人民币 6,841,824.00元加上同期银行存款利息之和。 ●经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次限制性 股票回购注销事宜已于2024年4月17日办理完成。回购完成后，公司股份总数由 370,770,580股变更为369,767,380股。 保龄宝生物股份有限公司（以下简称"公司"）于2024年3月8日召开第五届 董事会第二十六次会议、第五届监事会第二十三次会议审议通过了《关于调整 2021年股票期权与限制性股票激励计划回购价格及回购注销部分限制性股票的 议案》，鉴于《保龄宝生物股份有限公司2021年股票期权与限制性股票激励计 划》（以下简称"《激 ...

证券代码：002286 证券简称：保龄宝 公告编号：2024-031 保龄宝生物股份有限公司独立董事候选人声明与承诺 声明人 肖华孝 作为保龄宝生物股份有限公司第 6 届 董事会独立董事候选人，已充分了解并同意由提名人北京 永裕投资管理有限公司提名为保龄宝生物股份有限公司 （以下简称该公司）第 6 届董事会独立董事候选人。现公开 声明和保证，本人与该公司之间不存在任何影响本人独立 性的关系，且符合相关法律、行政法规、部门规章、规范性 文件和深圳证券交易所业务规则对独立董事候选人任职资 格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过保龄宝生物股份有限公司第 5 届董 事会提名委员会或者独立董事专门会议资格审查，提名人 与本人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百四十 六条等规定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理 ...

股票简称：保龄宝 股票代码：002286 公告编号：2024-026 第五届董事会第二十七次会议决议公告 保龄宝生物股份有限公司 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记 录、误导性陈述或者重大遗漏。 一、会议召开情况 保龄宝生物股份有限公司（以下简称"保龄宝"或"公司"）关于召开第五届董 事会第二十七次会议的通知于 2024 年 4 月 3 日以电子邮件的方式发出，会议于 2024 年 4 月 9 日以通讯表决的方式召开。会议应出席董事 8 人，实际出席董事 8 人。会议召集、召开程序符合有关法律、行政法规、规范性文件和《公司章程》 的有关规定。 二、会议审议情况 1、审议通过了《关于公司董事会换届选举暨提名第六届董事会非独立董事 候选人的议案》； 公司第五届董事会任期已经届满，根据《中华人民共和国公司法》、《深 圳证券交易所股票上市规则》等法律法规、规范性文件及《公司章程》的有关 规定，公司股东北京永裕投资管理有限公司提名戴斯觉先生、王强先生、秦翠 萍女士为第六届董事会非独立董事候选人；公司股东宁波趵朴富通资产管理中 心（有限合伙）提名李洪波先生为第六届董事会非独立董事候选人；公司 ...

如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百 四十六条等规定不得担任公司董事的情形。 提名人北京永裕投资管理有限公司现就提名赵小莲为 保龄宝生物股份有限公司第 6 届董事会独立董事候选人发 表公开声明。被提名人已书面同意作为保龄宝生物股份有 限公司第 6 届董事会独立董事候选人（参见该独立董事候 选人声明）。本次提名是在充分了解被提名人职业、学历、 职称、详细的工作经历、全部兼职、有无重大失信等不良记 录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规 则对独立董事候选人任职资格及独立性的要求，具体声明 并承诺如下事项： 一、被提名人已经通过保龄宝生物股份有限公司第 5 届 董事会提名委员会或者独立董事专门会议资格审查，提名 人与被提名人不存在利害关系或者其他可能影响独立履职 情形的密切关系。 ☑ 是 □ 否 证券代码：002286 证券简称：保龄宝 公告编号：2024-034 保龄宝生物股份有限公司独立董事提名人声明与承诺 ☑ 是 □ 否 如否，请详细说明：______ ...